Compare ALKS & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALKS | CRSP |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | Ireland | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.9B |
| IPO Year | 2012 | 2016 |
| Metric | ALKS | CRSP |
|---|---|---|
| Price | $38.99 | $53.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 17 |
| Target Price | $43.43 | ★ $70.29 |
| AVG Volume (30 Days) | ★ 1.7M | 1.7M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,475,899,000.00 | $289,590,000.00 |
| Revenue This Year | $24.26 | $807.72 |
| Revenue Next Year | $4.47 | $172.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $25.17 | $34.87 |
| 52 Week High | $38.45 | $78.48 |
| Indicator | ALKS | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 71.82 | 50.38 |
| Support Level | $27.65 | $50.74 |
| Resistance Level | N/A | $60.45 |
| Average True Range (ATR) | 1.29 | 2.88 |
| MACD | 0.34 | -0.07 |
| Stochastic Oscillator | 87.89 | 54.10 |
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.